# BAM-15

> BAM-15 is a mitochondrial uncoupling compound studied in preclinical research for its potential to increase energy expenditure without the severe mitochondrial membrane depolarization associated with older uncoupling agents. Animal studies have reported increased metabolic rate and resistance to diet-induced weight gain. There is essentially no published human clinical trial data, and it is not an approved or clinically validated weight-management therapy. It remains a subject of early-stage laboratory and animal research.

- URL: https://www.lifeconverted.com/peptides/bam-15
- Primary category: Weight Management
- Effectiveness rank: #24 in Weight Management; #14 in Metabolic
- Evidence level: Emerging research
- Route: Oral (Human dosing has not been established; available data come almost entirely from animal and cell-based studies.)
- Dose range: 25-100 mg
- Dose tiers: low 25 mg; moderate 50 mg; high 100 mg
- Half-life: Not established in humans; preclinical pharmacokinetic data are limited
- Timing: Morning
- Cycle: No established human protocol on, No established human protocol off (All available dosing information is extrapolated from animal studies and should not be treated as validated for human use.)
- Storage: Store as a research chemical per supplier instructions, typically at room temperature or refrigerated, protected from light and moisture; not manufactured or labeled as a human pharmaceutical.

## Mechanism of action

BAM-15 mildly uncouples mitochondrial oxidative phosphorylation from ATP production, causing cells to burn additional substrate (fat and glucose) to generate heat rather than usable energy, without collapsing the mitochondrial membrane potential as older uncouplers such as DNP did. This is proposed to raise overall energy expenditure while avoiding some of the acute toxicity associated with earlier uncoupling agents, based on animal studies.

## Reported benefits

- Increased energy expenditure reported in animal studies
- Resistance to diet-induced weight gain observed in preclinical models
- Proposed improved safety margin relative to older mitochondrial uncouplers, based on animal data
- Distinct mechanism from incretin- and appetite-based weight agents

## Reported side effects

- Human safety profile is not established
- Theoretical risk of excessive metabolic stress or hyperthermia based on the mitochondrial uncoupling mechanism
- Unknown interaction risk with other metabolic or cardiovascular medications
- Long-term effects in humans have not been studied

## Common protocols

- No standardized human protocol exists; use is confined to preclinical animal research to date

## Stacking notes

Not established; no controlled human data exist on combination with other metabolic agents.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer